KCI’s LifeCell™ Business Names Michael G. Franz, M.D. Vice President of Global Clinical & Medical Affairs
26 Octubre 2011 - 9:52AM
Business Wire
Kinetic Concepts, Inc. (NYSE: KCI), announced today that Michael
G. Franz, M.D., FACS, has been named vice president of Global
Clinical & Medical Affairs for LifeCell™, a business unit of
KCI that specializes in regenerative medicine.
As VP of Global Clinical & Medical Affairs for LifeCell™,
Franz will be responsible for establishing overall clinical and
medical strategies, completing clinical studies and providing input
into new product activities. He will also work closely with the
commercial and research & development teams company-wide.
Franz most recently served as chief, Division of Minimally
Invasive Surgery, University of Michigan Department of Surgery,
Section of General Surgery. He has more than 20 years of surgical
medical experience and is a globally recognized leader and
published researcher in the field of wound healing, abdominal wall
pathophysiology, tissue engineering and surgical innovation. He
previously served on KCI’s Scientific Advisory Board, a committee
of leading clinical experts that provides medical guidance to the
company.
“Mike shares KCI’s deep passion for regenerative medicine, the
advancement of surgical techniques and maximizing patient
outcomes,” said Lisa Colleran, president, LifeCell™. “As we
continue to grow and launch more products in more places, his
expertise in clinical evidence and patient efficacy, and his
research in wound healing and tissue engineering around the world,
will greatly contribute to our continued success and
innovation.”
"Mike is an internationally recognized expert and authority in
the field of biologics and biologic materials," said Ron Silverman,
M.D., chief medical officer, KCI. "His scientific and critical
thinking will further KCI's commitment to improving the lives of
patients."
About KCI
Kinetic Concepts, Inc. (NYSE:KCI) is a leading global medical
technology company devoted to the discovery, development,
manufacture and marketing of innovative, high-technology therapies
and products for the wound care, tissue regeneration and
therapeutic support system markets. Headquartered in San Antonio,
Texas, KCI's success spans more than three decades and can be
traced to a history deeply rooted in innovation and a passion for
significantly improving the healing and the lives of patients
around the world. The company employs approximately 7,100 people
and markets its products in more than 20 countries. For more
information about KCI and how its products are changing the
practice of medicine, visit www.KCI1.com.
Kinetic Concepts (NYSE:KCI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Kinetic Concepts (NYSE:KCI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024